Raymond James & Associates Editas Medicine, Inc. Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

A detailed history of Raymond James & Associates transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 561,371 shares of EDIT stock, worth $1.24 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
561,371
Previous 526,815 6.56%
Holding current value
$1.24 Million
Previous $2.46 Million 22.2%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024
BUY
$3.39 - $5.96 $117,144 - $205,953
34,556 Added 6.56%
561,371 $1.91 Million
Q2 2024

Jul 19, 2024
BUY
$4.67 - $7.28 $817,217 - $1.27 Million
174,993 Added 49.74%
526,815 $2.46 Million
Q1 2024

Apr 22, 2024
BUY
$7.03 - $11.07 $652,123 - $1.03 Million
92,763 Added 35.81%
351,822 $2.61 Million
Q4 2023

Jan 16, 2024
SELL
$6.25 - $11.11 $95,275 - $169,360
-15,244 Reduced 5.56%
259,059 $2.62 Million
Q3 2023

Oct 24, 2023
BUY
$6.92 - $9.31 $103,758 - $139,594
14,994 Added 5.78%
274,303 $2.14 Million
Q2 2023

Jul 25, 2023
BUY
$6.36 - $11.47 $983,039 - $1.77 Million
154,566 Added 147.57%
259,309 $2.13 Million
Q1 2023

Apr 14, 2023
BUY
$7.03 - $11.53 $52,837 - $86,659
7,516 Added 7.73%
104,743 $759,000
Q4 2022

Feb 08, 2023
BUY
$8.32 - $13.21 $94,174 - $149,523
11,319 Added 13.18%
97,227 $862,000
Q3 2022

Oct 25, 2022
SELL
$12.16 - $19.42 $639,263 - $1.02 Million
-52,571 Reduced 37.96%
85,908 $1.05 Million
Q2 2022

Aug 12, 2022
SELL
$9.99 - $21.35 $216,203 - $462,056
-21,642 Reduced 13.52%
138,479 $1.64 Million
Q1 2022

May 11, 2022
BUY
$14.08 - $27.63 $1.42 Million - $2.79 Million
100,971 Added 170.7%
160,121 $3.05 Million
Q4 2021

Feb 08, 2022
SELL
$26.55 - $40.57 $125,077 - $191,125
-4,711 Reduced 7.38%
59,150 $1.57 Million
Q3 2021

Nov 02, 2021
BUY
$39.27 - $72.94 $19,556 - $36,324
498 Added 0.79%
63,861 $2.62 Million
Q2 2021

Aug 11, 2021
SELL
$31.29 - $56.64 $577,738 - $1.05 Million
-18,464 Reduced 22.56%
63,363 $3.59 Million
Q1 2021

May 14, 2021
BUY
$39.71 - $90.58 $813,459 - $1.86 Million
20,485 Added 33.39%
81,827 $3.44 Million
Q4 2020

Feb 12, 2021
SELL
$27.07 - $84.35 $546,597 - $1.7 Million
-20,192 Reduced 24.77%
61,342 $4.3 Million
Q3 2020

Nov 04, 2020
SELL
$28.06 - $37.16 $519,166 - $687,534
-18,502 Reduced 18.5%
81,534 $2.29 Million
Q2 2020

Jul 28, 2020
BUY
$18.5 - $34.34 $99,530 - $184,749
5,380 Added 5.68%
100,036 $2.96 Million
Q1 2020

Apr 21, 2020
BUY
$14.88 - $32.78 $629,691 - $1.39 Million
42,318 Added 80.86%
94,656 $1.88 Million
Q4 2019

Feb 12, 2020
SELL
$19.49 - $32.63 $152,138 - $254,709
-7,806 Reduced 12.98%
52,338 $1.55 Million
Q3 2019

Nov 07, 2019
BUY
$22.49 - $26.81 $29,147 - $34,745
1,296 Added 2.2%
60,144 $1.37 Million
Q2 2019

Aug 06, 2019
BUY
$20.48 - $27.76 $861,184 - $1.17 Million
42,050 Added 250.33%
58,848 $1.46 Million
Q1 2019

May 06, 2019
SELL
$19.43 - $26.41 $224,377 - $304,982
-11,548 Reduced 40.74%
16,798 $411,000
Q4 2018

Feb 11, 2019
SELL
$18.19 - $31.79 $98,808 - $172,683
-5,432 Reduced 16.08%
28,346 $645,000
Q3 2018

Nov 14, 2018
BUY
$27.65 - $38.39 $41,613 - $57,776
1,505 Added 4.66%
33,778 $1.08 Million
Q2 2018

Aug 14, 2018
BUY
$31.4 - $41.01 $5,400 - $7,053
172 Added 0.54%
32,273 $1.16 Million
Q1 2018

May 14, 2018
BUY
$29.84 - $44.08 $957,893 - $1.42 Million
32,101 New
32,101 $1.06 Million

Others Institutions Holding EDIT

# of Institutions
224
Shares Held
48.2M
Call Options Held
436K
Put Options Held
324K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $152M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email